Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy

Biomaterials

Volumn 34, Issue 4, 2013, Pages 1255-1260

  Talelli, Marina ^a   Oliveira, Sabrina ^b   Rijcken, Cristianne J F ^a,c   Pieters, Ebel H E ^a   Etrych, Tomas ^d   Ulbrich, Karel ^d   van Nostrum, Rene C F ^a   Storm, Gert ^a,e   Hennink, Wim E ^a   Lammers, Twan ^a,e,f  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Cristal Delivery BV   (Netherlands)

^d INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

^e UNIVERSITY OF TWENTE   (Netherlands)

^f RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Active targeting; Cancer; EGFR; Micelle; Nanobody; Nanomedicine

Indexed keywords

ACTIVE TARGETING; CANCER; CARRIER MATERIAL; CHEMOTHERAPEUTIC AGENTS; COMBINATION THERAPY; CYTOSTATIC ACTIVITIES; DOXORUBICIN; EGFR; IN-VIVO; NANOBODY; NANOMEDICINES; PHARMACOLOGICAL ACTIVITY; POLYMERIC MICELLE; THERAPEUTIC STRATEGY; TUMOR GROWTH;

DISEASES; LIGANDS; MEDICAL NANOTECHNOLOGY; MICELLES; TUMORS;

POLYMERS;

6 METHACRYLAMIDOHEXANOHYDRAZIDE; COPOLYMER; DOXORUBICIN; DRUG CARRIER; EGA1 NANOBODY; MACROGOL DERIVATIVE; METHACRYLIC ACID; POLYMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; COMPARATIVE STUDY; CONTROLLED STUDY; COVALENT BOND; CRITICAL MICELLE CONCENTRATION; CROSS LINKING; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG TARGETING; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; LIGAND BINDING; LOW DRUG DOSE; MALE; MICELLE; NANOBODY MODIFIED POLYMERIC MICELLE; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR VOLUME;

ANIMALS; DIFFUSION; DOXORUBICIN; DRUG COMBINATIONS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICELLES; NANOCAPSULES; NEOPLASMS, EXPERIMENTAL; POLYMERS; TREATMENT OUTCOME;

EID: 84870351860     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.09.064     Document Type: Article

References (31)

1. Gu F.X., Karnik R., Wang A.Z., Alexis F., Levy-Nissenbaum E., Hong S., et al. Targeted nanoparticles for cancer therapy. Nano Today 2007, 2:14-21.
2. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001, 53:283-318.
3. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
4. Davis M.E., Chen Z., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771-782.
5. Duncan R., Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm 2011, 8:2101-2141.
6. Lammers T., Hennink W.E., Storm G. Tumour-targeted nanomedicines: principles and practice. Br J Cancer 2008, 99:392-397.
7. Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J Control Release, http://dx.doi.org/10.1016/j.jconrel.2012.04.038.
8. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46:6387-6392.
9. Seymour L.W. Passive tumor targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Syst 1992, 9:135-187.
10. Jain R.K., Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010, 7:653-664.
11. Lammers T., Kiessling F., Hennink W.E., Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release 2012, 161:175-187.
12. Lammers T. Nanomedicine on the move: from monotherapeutic regimens to combination therapies. Exp Rev Clin Pharm 2012, 5:105-108.
13. Greco F., Vicent M.J. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev 2009, 61:1203-1213.
14. Lammers T. Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations. Adv Drug Deliv Rev 2010, 62:203-230.
15. Lammers T., Subr V., Ulbrich K., Hennink W.E., Storm G., Kiessling F. Polymeric nanomedicines for image-guided drug delivery and tumor-targeted combination therapy. Nano Today 2010, 5:197-212.
16. Kirpotin D.B., Drummond D.C., Shao Y., Shalaby M.R., Hong K., Nielsen U.B., et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006, 66:6732-6740.
17. Choi C.H.J., Alabi C.A., Webster P., Davis M.E. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci U S A 2010, 107:1235-1240.
18. Bartlett D.W., Su H., Hildebrandt I.J., Weber W.A., Davis M.E. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A 2007, 104:15549-15554.
19. Davis M.E. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 2009, 6:659-668.
20. Muyldermans S., Baral T.N., Retamozzo V.C., De Baetselier P., De Genst E., Kinne J., et al. Camelid immunoglobulins and nanobody technology. Vet Immunol Immunopathol 2009, 128:178-183.
21. Talelli M., Iman M., Varkouhi A.K., Rijcken C.J., Schiffelers R.M., Etrych T., et al. Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin. Biomaterials 2010, 31:7797-7804.
22. Etrych T., Mrkvan T., Chytil P., Konak C., Rihova B., Ulbrich K. N-(2-hydroxypropyl)methacrylamide-based polymer conjugates with pH-controlled activation of doxorubicin. I. New synthesis, physicochemical characterization and preliminary biological evaluation. J Appl Polym Sci 2008, 109:3050-3061.
23. Oliveira S., Schiffelers R.M., van der Veeken J., van der Meel R., Vongpromek R., van Bergen En Henegouwen P.M., et al. Downregulation of EGFR by a novel multivalent nanobody-liposome platform. J Control Release 2010, 145:165-175.
24. Talelli M., Rijcken C.J., Oliveira S., van der Meel R., van Bergen En Henegouwen P.M., Lammers T., et al. Nanobody-shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting. J Control Release 2011, 151:183-192.
25. Rijcken C.J., Snel C.J., Schiffelers R.M., van Nostrum C.F., Hennink W.E. Hydrolysable core-crosslinked thermosensitive polymeric micelles: synthesis, characterisation and in vivo studies. Biomaterials 2007, 28:5581-5593.
26. Carey T.E. Head and neck tumor cell lines. Atlas of human tumor cell lines 1994, 79. Academic Press, San Diego, California. R. Hay (Ed.).
27. Soga O., van Nostrum C.F., Ramzi A., Visser T., Soulimani F., Frederik P.M., et al. Physicochemical characterization of degradable thermosensitive polymeric micelles. Langmuir 2004, 20:9388-9395.
28. Neradovic D., Soga O., van Nostrum C.F., Hennink W.E. The effect of the processing and formulation parameters on the size of nanoparticles based on block copolymers of poly(ethylene glycol) and poly(N-isopropylacrylamide) with and without hydrolytically sensitive groups. Biomaterials 2004, 25:2409-2418.
29. Byrne J.D., Betancourt T., Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 2008, 60:1615-1626.
30. Torchilin V.P. Drug targeting. Eur J Pharm Sci 2000, 11(Suppl. 2):S81-S91.
31. Stastny M., Plocova D., Etrych T., Ulbrich K., Rihova B. HPMA-hydrogels result in prolonged delivery of anticancer drugs and are a promising tool for the treatment of sensitive and multidrug resistant leukaemia. Eur J Cancer 2002, 38:602-608.